| Compound | Epitalon |
|---|---|
| Category | Khavinson telomerase peptide |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers Epitalon, a khavinson telomerase peptide, graded "Minimal evidence" in this catalog's evidence system. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A four-amino-acid peptide (Ala-Glu-Asp-Gly) developed in the Soviet peptide-bioregulation program and studied for pineal and telomerase effects, with anti-aging claims attached.
Mechanism of Action
Animal studies report effects on pineal hormone secretion and — controversially — telomerase activation; mechanism claims outpace replication.
Research and Evidence
Evidence consists of animal work and small Russian human studies; no trials meet international standards.
Safety and Side Effects
No robust human safety database; telomerase activation in a clinical vacuum is a theoretical oncogenic concern.
Frequently Asked Questions
What is the evidence tier of Epitalon?
Epitalon is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Epitalon an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Epitalon?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for Epitalon studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.